Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2013 4
2014 5
2015 11
2016 5
2017 6
2018 8
2019 11
2020 10
2021 17
2022 24
2023 22
2024 17
2025 34
2026 17

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

166 results

Results by year

Filters applied: . Clear all
Page 1
Oclacitinib 10 years later: lessons learned and directions for the future.
Marsella R, Doerr K, Gonzales A, Rosenkrantz W, Schissler J, White A. Marsella R, et al. J Am Vet Med Assoc. 2023 Mar 25;261(S1):S36-S47. doi: 10.2460/javma.22.12.0570. Print 2023 Jun 1. J Am Vet Med Assoc. 2023. PMID: 36944222 Free article. Review.
Oclacitinib was approved in the United States 10 years ago for the management of atopic dermatitis (AD) and allergic skin disease in dogs. ...The purpose of this review is to present the current knowledge on the efficacy, speed of action, effects on the immune system, and …
Oclacitinib was approved in the United States 10 years ago for the management of atopic dermatitis (AD) and allergic skin disease in …
Safety of the Selective JAK1 Inhibitor Oclacitinib in Dogs.
Nederveld SM, Krautmann MJ, Mitchell J. Nederveld SM, et al. J Vet Pharmacol Ther. 2025 May;48(3):135-145. doi: 10.1111/jvp.13503. Epub 2025 Feb 28. J Vet Pharmacol Ther. 2025. PMID: 40018984 Free PMC article. Review.
The safety of oclacitinib has been extensively evaluated in investigational and independent studies. In the oclacitinib postapproval PV surveillance, the types and rank order of frequency of reported adverse events were similar to the premarketing field studies, wit …
The safety of oclacitinib has been extensively evaluated in investigational and independent studies. In the oclacitinib postap …
Comparative efficacy and safety of ilunocitinib and oclacitinib for the control of pruritus and associated skin lesions in dogs with atopic dermatitis.
Forster S, Boegel A, Despa S, Trout C, King S. Forster S, et al. Vet Dermatol. 2025 Apr;36(2):165-176. doi: 10.1111/vde.13319. Epub 2025 Jan 6. Vet Dermatol. 2025. PMID: 39757965 Free PMC article.
PVAS scores increased between D14 and D28 for oclacitinib and decreased for ilunocitinib. On D28 to D112, mean PVAS and CADESI-04 scores were significantly lower for ilunocitinib compared to oclacitinib (p 0.003 and p 0.023, respectively). ...Ilunocitinib demons …
PVAS scores increased between D14 and D28 for oclacitinib and decreased for ilunocitinib. On D28 to D112, mean PVAS and CADESI-04 sco …
Oclacitinib Intoxication.
Lister S, Basile JK, Wegenast C. Lister S, et al. J Vet Emerg Crit Care (San Antonio). 2025 Mar-Apr;35(2):176-177. doi: 10.1111/vec.13459. Epub 2025 Apr 20. J Vet Emerg Crit Care (San Antonio). 2025. PMID: 40254916 Free PMC article.
BACKGROUND: Since the release of chewable flavored oclacitinib, household pets are ingesting larger quantities and are experiencing signs of toxicosis that have not been noted previously. ...
BACKGROUND: Since the release of chewable flavored oclacitinib, household pets are ingesting larger quantities and are experiencing s …
Efficacy of oclacitinib for the control of feline atopic skin syndrome: correlating plasma concentrations with clinical response.
Carrasco I, Ferrer L, Puigdemont A. Carrasco I, et al. J Feline Med Surg. 2022 Aug;24(8):787-793. doi: 10.1177/1098612X211048458. Epub 2021 Oct 6. J Feline Med Surg. 2022. PMID: 34612749 Free PMC article.
METHODS: Twenty-eight client-owned cats with a clinical diagnosis of FASS were recruited. Oclacitinib was administered at 1 mg/kg q12h for 2 weeks and then at 1 mg/kg q24h for a further 2 weeks. ...Oclacitinib concentrations showed no correlation with clinical effec …
METHODS: Twenty-eight client-owned cats with a clinical diagnosis of FASS were recruited. Oclacitinib was administered at 1 mg/kg q12 …
[Oclacitinib in dogs - Janus kinase inhibition in veterinary dermatology].
Popp PJC, Mueller RS. Popp PJC, et al. Tierarztl Prax Ausg K Kleintiere Heimtiere. 2025 Jun;53(3):146-158. doi: 10.1055/a-2546-1573. Epub 2025 Jun 13. Tierarztl Prax Ausg K Kleintiere Heimtiere. 2025. PMID: 40513605 Review. German.
Oclacitinib (Apoquel, Zoetis) is currently the only Janus kinase inhibitor approved for veterinary medicine in the EU. ...An overview of the successful use of oclacitinib in other immune-mediated diseases is presented....
Oclacitinib (Apoquel, Zoetis) is currently the only Janus kinase inhibitor approved for veterinary medicine in the EU. ...An overview …
Oclacitinib (APOQUEL ) is a selective Janus kinase 1 inhibitor with efficacy in a canine model of flea allergic dermatitis.
Gonzales AJ, Aleo M, Mahabir S, Messamore J, Stegemann M. Gonzales AJ, et al. J Vet Pharmacol Ther. 2024 Nov;47(6):447-453. doi: 10.1111/jvp.13462. Epub 2024 Jun 26. J Vet Pharmacol Ther. 2024. PMID: 38926932
Oclacitinib is a novel Janus kinase (JAK) inhibitor that potently inhibits JAK1-dependent cytokines involved in allergy, inflammation, and pruritus (IL-2, IL-4, IL-6, IL-13, and IL-31). ...Oclacitinib also significantly reduced erythema (p < .0001) and skin lesio …
Oclacitinib is a novel Janus kinase (JAK) inhibitor that potently inhibits JAK1-dependent cytokines involved in allergy, inflammation …
Short-term administration of oclacitinib with concomitant medications in canine epitheliotropic lymphoma: A retrospective study of eight dogs.
Baba Y, Asakura T, Obayashi S, Yamada M, Otsuka M, Morikawa S, Teh A, Mitsui I, Osumi T. Baba Y, et al. Vet Dermatol. 2025 Oct;36(5):660-667. doi: 10.1111/vde.13366. Epub 2025 Jun 17. Vet Dermatol. 2025. PMID: 40525607
MATERIALS AND METHODS: The dogs were administered oclacitinib. This study examined the immunological characteristics, time to treatment initiation, dosage, cutaneous lesions and pruritus, adverse events, survival time and prior oclacitinib use. ...CONCLUSIONS AND CL …
MATERIALS AND METHODS: The dogs were administered oclacitinib. This study examined the immunological characteristics, time to treatme …
Treatment of the feline atopic syndrome - a systematic review.
Mueller RS, Nuttall T, Prost C, Schulz B, Bizikova P. Mueller RS, et al. Vet Dermatol. 2021 Feb;32(1):43-e8. doi: 10.1111/vde.12933. Vet Dermatol. 2021. PMID: 33470011
CONCLUSION AND CLINICAL RELEVANCE: In this review, there was good evidence for the efficacy of systemic glucocorticoids and ciclosporin, and limited evidence for the efficacy of topical glucocorticoids, oclacitinib and allergen-specific immunotherapy in feline atopic skin …
CONCLUSION AND CLINICAL RELEVANCE: In this review, there was good evidence for the efficacy of systemic glucocorticoids and ciclosporin, and …
Effective treatment of canine chronic cutaneous lupus erythematosus variants with oclacitinib: Seven cases.
Harvey RG, Olivrī A, Lima T, Olivry T. Harvey RG, et al. Vet Dermatol. 2023 Feb;34(1):53-58. doi: 10.1111/vde.13128. Epub 2022 Oct 13. Vet Dermatol. 2023. PMID: 36229964 Free PMC article.
OBJECTIVES: To report the efficacy and safety of oral oclacitinib for the treatment of canine CCLE variants. ANIMALS: Seven dogs were diagnosed with CCLE based on clinical signs and compatible histopathological findings. MATERIALS AND METHODS: Oclacitinib was admini …
OBJECTIVES: To report the efficacy and safety of oral oclacitinib for the treatment of canine CCLE variants. ANIMALS: Seven dogs were …
166 results